title: Therapeutic efficacy of 188Re-MN-16ET lipiodol in an animal model of hepatocellular carcinoma.
abstract: OBJECTIVE
  In our recent study, we developed a new radiopharmaceutical (Re-188 MN-16ET lipiodol) with encouraging results for the treatment of liver malignancy. In this study, we further evaluated the therapeutic efficacy of this radiopharmaceutical by measuring tumor response and survival times in rats with liver tumors after intra-hepatic arterial injection of Re-188 MN-16ET lipiodol.
  
  
  METHODS
  Twelve male rats bearing hepatic tumors were divided into three groups. Group 1 received an intra-hepatic arterial injection of 18.5 MBq Re-188 MN-16ET lipiodol; Group 2 received lipiodol and Group 3 received normal saline. Tumor size was measured by liver sonography before injection, at 2, 4, and 8 weeks after injection. Survival time and response rate were calculated.
  
  
  RESULTS
  All rats showed good response and survived over 60 days in Group 1 while all rats showed poor response in Group 2 and Group 3 with only 25 % of rats in Group 2 and none (0 %) in Group 3 survived over 60 days. The p value was 0.0067 between Group 1 and Group 3; 0.04 between Group 1 and Group 2; and 0.034 between Group 2 and Group 3.
  
  
  CONCLUSIONS
  Re-188 MN-16ET lipiodol has good potential for the treatment of hepatoma.
authors.affiliation: Department of Emergency, Show-Chwan Memorial Hospital, Changhua, Taiwan.
authors.forename: Ping-Wun
authors.initials: PW
authors.lastname: Huang
authors.forename: Shih-Chung
authors.initials: SC
authors.lastname: Tsai
authors.forename: Tsai-Yueh
authors.initials: TY
authors.lastname: Luo
authors.forename: Chia-Hung
authors.initials: CH
authors.lastname: Kao
authors.forename: Wan-Yu
authors.initials: WY
authors.lastname: Lin
mesh_terms: D000818:Animals; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000532:radiotherapy*; D004195:Disease Models, Animal; D004998:Ethiodized Oil / Q000737:chemistry / Q000627:therapeutic use*; D005998:Glycine / Q000031:analogs & derivatives* / Q000737:chemistry; D008113:Liver Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D010169:Palmitic Acids / Q000737:chemistry*; D011868:Radioisotopes / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012211:Rhenium / Q000627:therapeutic use*; D015996:Survival Rate; D016896:Treatment Outcome; D047368:Tumor Burden
chemical_list: C569623:N-(2-(triphenylmethyl)thioethyl)-3-aza-19-ethyloxycarbonyl-3-(2-(triphenylmethyl)thioethyl)octadecanoate; D010169:Palmitic Acids; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D012211:Rhenium; D004998:Ethiodized Oil; D005998:Glycine